 Drew Kern
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 19 | 2026 | 220 | 5.100 |
Why?
| | Parkinson Disease | 28 | 2026 | 601 | 4.830 |
Why?
| | Subthalamic Nucleus | 9 | 2025 | 84 | 3.140 |
Why?
| | Tremor | 5 | 2023 | 98 | 1.110 |
Why?
| | Beta Rhythm | 2 | 2025 | 33 | 0.940 |
Why?
| | Globus Pallidus | 2 | 2021 | 25 | 0.800 |
Why?
| | Dystonia | 3 | 2020 | 27 | 0.790 |
Why?
| | Thalamus | 2 | 2021 | 129 | 0.730 |
Why?
| | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 5 | 2022 | 11 | 0.720 |
Why?
| | Methylphenidate | 1 | 2022 | 49 | 0.700 |
Why?
| | Dystonic Disorders | 1 | 2021 | 27 | 0.690 |
Why?
| | Zona Incerta | 1 | 2021 | 3 | 0.680 |
Why?
| | Caudate Nucleus | 1 | 2020 | 22 | 0.640 |
Why?
| | Putamen | 1 | 2020 | 23 | 0.640 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2019 | 22 | 0.600 |
Why?
| | Parkinsonian Disorders | 1 | 2019 | 43 | 0.580 |
Why?
| | Dopaminergic Neurons | 1 | 2019 | 68 | 0.570 |
Why?
| | Epilepsies, Myoclonic | 1 | 2019 | 59 | 0.560 |
Why?
| | Essential Tremor | 3 | 2026 | 24 | 0.510 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 2 | 2026 | 13 | 0.450 |
Why?
| | Palatal Muscles | 1 | 2015 | 5 | 0.450 |
Why?
| | Behavior Therapy | 1 | 2015 | 296 | 0.350 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2010 | 42 | 0.320 |
Why?
| | Serine Endopeptidases | 1 | 2010 | 129 | 0.300 |
Why?
| | tau Proteins | 1 | 2010 | 105 | 0.300 |
Why?
| | Extracellular Matrix Proteins | 1 | 2010 | 156 | 0.290 |
Why?
| | Neural Stem Cells | 1 | 2010 | 168 | 0.280 |
Why?
| | Humans | 38 | 2026 | 145763 | 0.270 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 592 | 0.240 |
Why?
| | Wakefulness | 2 | 2025 | 170 | 0.240 |
Why?
| | Male | 22 | 2026 | 73003 | 0.240 |
Why?
| | Treatment Outcome | 6 | 2026 | 11793 | 0.240 |
Why?
| | Middle Aged | 14 | 2026 | 36302 | 0.240 |
Why?
| | Carbidopa | 1 | 2026 | 10 | 0.240 |
Why?
| | Levodopa | 1 | 2026 | 40 | 0.230 |
Why?
| | Antiparkinson Agents | 1 | 2026 | 41 | 0.230 |
Why?
| | Patient Acceptance of Health Care | 2 | 2026 | 883 | 0.220 |
Why?
| | Mutation | 5 | 2022 | 4090 | 0.210 |
Why?
| | Hippocampus | 1 | 2010 | 973 | 0.210 |
Why?
| | Skull | 1 | 2026 | 163 | 0.210 |
Why?
| | Nervous System Diseases | 1 | 2007 | 286 | 0.210 |
Why?
| | Aged | 13 | 2026 | 26215 | 0.200 |
Why?
| | Down Syndrome | 1 | 2010 | 525 | 0.200 |
Why?
| | Arm | 2 | 2018 | 110 | 0.200 |
Why?
| | Multiple System Atrophy | 1 | 2023 | 8 | 0.190 |
Why?
| | Serine | 3 | 2018 | 143 | 0.180 |
Why?
| | Actigraphy | 2 | 2025 | 148 | 0.180 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2022 | 22 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2026 | 480 | 0.170 |
Why?
| | Tic Disorders | 1 | 2021 | 10 | 0.170 |
Why?
| | Fluvoxamine | 1 | 2021 | 18 | 0.170 |
Why?
| | Serotonin Antagonists | 1 | 2021 | 32 | 0.170 |
Why?
| | Risperidone | 1 | 2021 | 30 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 2 | 2026 | 3915 | 0.160 |
Why?
| | Dystonia Musculorum Deformans | 1 | 2020 | 3 | 0.160 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2021 | 46 | 0.160 |
Why?
| | Circadian Rhythm | 1 | 2025 | 513 | 0.160 |
Why?
| | Polyethylene Glycols | 3 | 2011 | 649 | 0.160 |
Why?
| | Voice Disorders | 1 | 2020 | 23 | 0.160 |
Why?
| | Electric Impedance | 1 | 2020 | 108 | 0.160 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2021 | 61 | 0.160 |
Why?
| | Hypokinesia | 1 | 2020 | 11 | 0.160 |
Why?
| | alpha-Synuclein | 2 | 2023 | 46 | 0.150 |
Why?
| | Glycine | 2 | 2018 | 186 | 0.150 |
Why?
| | Atrophy | 1 | 2020 | 199 | 0.150 |
Why?
| | Female | 17 | 2026 | 79035 | 0.150 |
Why?
| | Leg | 1 | 2001 | 242 | 0.150 |
Why?
| | Neuroglia | 2 | 2011 | 174 | 0.150 |
Why?
| | Health Literacy | 1 | 2022 | 186 | 0.150 |
Why?
| | Brain | 5 | 2022 | 2969 | 0.150 |
Why?
| | Tubulin | 1 | 2020 | 146 | 0.150 |
Why?
| | Adult | 8 | 2025 | 40872 | 0.140 |
Why?
| | Epileptic Syndromes | 1 | 2019 | 98 | 0.140 |
Why?
| | Biological Variation, Individual | 1 | 2018 | 2 | 0.140 |
Why?
| | Voice | 1 | 2018 | 12 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2021 | 219 | 0.130 |
Why?
| | Sleep | 1 | 2025 | 889 | 0.130 |
Why?
| | Spasms, Infantile | 1 | 2019 | 138 | 0.130 |
Why?
| | Family Health | 1 | 2018 | 191 | 0.130 |
Why?
| | Decision Making | 1 | 2024 | 982 | 0.130 |
Why?
| | Neuropsychological Tests | 1 | 2022 | 1137 | 0.130 |
Why?
| | REM Sleep Behavior Disorder | 1 | 2016 | 17 | 0.120 |
Why?
| | Sex Characteristics | 2 | 2017 | 789 | 0.120 |
Why?
| | Biocompatible Materials | 2 | 2010 | 429 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 337 | 0.100 |
Why?
| | Heart Diseases | 1 | 2017 | 341 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3416 | 0.090 |
Why?
| | Heart Rate | 1 | 2017 | 856 | 0.090 |
Why?
| | Colon | 1 | 2015 | 309 | 0.090 |
Why?
| | Hydrogels | 2 | 2010 | 701 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1791 | 0.080 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2011 | 17 | 0.080 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 44 | 0.080 |
Why?
| | Movement | 2 | 2026 | 293 | 0.080 |
Why?
| | Time Factors | 2 | 2020 | 7133 | 0.080 |
Why?
| | Biomechanical Phenomena | 2 | 2026 | 860 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 736 | 0.080 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 80 | 0.080 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 154 | 0.080 |
Why?
| | Trisomy | 1 | 2010 | 78 | 0.080 |
Why?
| | Lactic Acid | 1 | 2011 | 295 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 675 | 0.070 |
Why?
| | Prospective Studies | 1 | 2021 | 8075 | 0.070 |
Why?
| | Movement Disorders | 1 | 2007 | 69 | 0.060 |
Why?
| | Infusions, Subcutaneous | 1 | 2026 | 23 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2026 | 17325 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2010 | 2191 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2018 | 8346 | 0.050 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2025 | 30 | 0.050 |
Why?
| | Drug Combinations | 1 | 2026 | 396 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2007 | 1270 | 0.050 |
Why?
| | Alzheimer Disease | 1 | 2010 | 630 | 0.050 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 85 | 0.050 |
Why?
| | Patient Selection | 1 | 2007 | 739 | 0.050 |
Why?
| | Basal Ganglia | 1 | 2023 | 57 | 0.050 |
Why?
| | Nerve Degeneration | 1 | 2023 | 49 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2010 | 4151 | 0.050 |
Why?
| | Epilepsy | 1 | 2007 | 390 | 0.050 |
Why?
| | Young Adult | 2 | 2020 | 14251 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2022 | 89 | 0.050 |
Why?
| | Lysosomes | 1 | 2022 | 131 | 0.040 |
Why?
| | Medicare | 2 | 2017 | 904 | 0.040 |
Why?
| | Upper Extremity | 1 | 2022 | 113 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2001 | 212 | 0.040 |
Why?
| | Animals | 5 | 2022 | 38097 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4568 | 0.040 |
Why?
| | Aging | 1 | 2010 | 1973 | 0.040 |
Why?
| | Mice | 2 | 2022 | 18355 | 0.040 |
Why?
| | Prosthesis Implantation | 2 | 2011 | 156 | 0.040 |
Why?
| | Pedigree | 1 | 2020 | 515 | 0.040 |
Why?
| | Electromyography | 1 | 2001 | 419 | 0.040 |
Why?
| | Fingers | 1 | 2020 | 107 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2001 | 429 | 0.040 |
Why?
| | Astrocytes | 2 | 2011 | 228 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2933 | 0.030 |
Why?
| | United States | 3 | 2025 | 16123 | 0.030 |
Why?
| | Mental Disorders | 1 | 2007 | 1169 | 0.030 |
Why?
| | Microglia | 2 | 2011 | 273 | 0.030 |
Why?
| | Phosphorylation | 1 | 2022 | 1708 | 0.030 |
Why?
| | Skin | 1 | 2023 | 754 | 0.030 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 6032 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1897 | 0.030 |
Why?
| | Dreams | 1 | 2016 | 14 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 868 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2001 | 935 | 0.030 |
Why?
| | Polysomnography | 1 | 2016 | 239 | 0.030 |
Why?
| | Sleep Deprivation | 1 | 2018 | 206 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 371 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2525 | 0.030 |
Why?
| | Patient Care Team | 1 | 2021 | 697 | 0.030 |
Why?
| | Paraffin Embedding | 1 | 2015 | 33 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 4302 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1122 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 668 | 0.020 |
Why?
| | Family | 1 | 2018 | 685 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2181 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2139 | 0.020 |
Why?
| | Rats | 2 | 2011 | 5585 | 0.020 |
Why?
| | Adolescent | 2 | 2020 | 22573 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1723 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2933 | 0.020 |
Why?
| | Compressive Strength | 1 | 2010 | 72 | 0.020 |
Why?
| | Prevalence | 1 | 2017 | 2874 | 0.020 |
Why?
| | Cell Count | 1 | 2011 | 319 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 2000 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3210 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 381 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2123 | 0.020 |
Why?
| | Haplorhini | 1 | 2008 | 52 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5922 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11868 | 0.010 |
Why?
| | Child | 1 | 2020 | 22739 | 0.010 |
Why?
|
|
Kern's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|